CytoDyn Inc. Form 8-K (Dec. 7, 2022)

Summary

Form 8-K current report of CytoDyn Inc. dated December 7, 2022, filed under Item 7.01 (Regulation FD Disclosure). It reports that on December 7, 2022 the company made a presentation during its R&D Update and posted it on the company's website. The investor presentation is furnished, not filed, as Exhibit 99.1. The report is signed by Antonio Migliarese.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 07, 2022 ( December 07, 2022 )

CytoDyn Inc.

(Exact name of registrant as specified in its charter)

Delaware | 000-49908 | 83-1887078
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.)

1111 Main Street , Suite 660

Vancouver , Washington 98660

(Address of principal executive offices, including zip code)

( 360 ) 980-8524

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
None | None | None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 7, 2022, CytoDyn Inc. (the “Company”) made a presentation during its R&D Update. The presentation has been posted on the Company’s website and a copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 | Investor Presentation dated December 7, 2022**
Exhibit 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL.

** Furnished, not filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYTODYN INC.
Date: December 7, 2022 | By | /s/ Antonio Migliarese
Antonio Migliarese
Chief Financial Officer

File and source

File

SEC_CYDY_8-K_filed2022-12-07_0001558370-22-018433.htm

Size

36,434 bytes

SHA-256

4cd51d3b45a7411ab9750d78fbdd0a7f99a99afc3b2f048b79a14e2360e2b777

Our copy

SEC_CYDY_8-K_filed2022-12-07_0001558370-22-018433.htm

Original

www.sec.gov

Exhibits

Exhibit 99.1: CytoDyn Inc., "R&D Investor Update" presentation, Dec. 7, 2022